(Q38192553)

English

Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae

scientific article published on 27 February 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

1 reference

Europe PubMed Central

Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Shannon A Novosad

1

object named as

S A Novosad

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

author name string

K L Winthrop

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

language of work or name

0 references

publication date

27 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

1587-1598

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Glucocorticoid use, other associated factors, and the risk of tuberculosis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk factors for Cryptococcus gattii infection, British Columbia, Canada

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Infectious complications associated with immunomodulating biologic agents.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Listeriosis in patients receiving biologic therapies

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Management of rheumatic disease with comorbid HBV or HCV infection.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Tumor necrosis factor blockade and the risk of viral infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

The risk of infections with biologic therapies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Abatacept mechanism of action: concordance with its clinical profile

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Abatacept treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Subcutaneous abatacept for the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Does rituximab aggravate pre-existing hypogammaglobulinaemia?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Rituximab administration and reactivation of HBV.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Tocilizumab: the first interleukin-6-receptor inhibitor

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Integrated safety in tocilizumab clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Preventing and treating biologic-associated opportunistic infections.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Let the fog be lifted: screening for hepatitis B virus before biological therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

The delivery of evidence-based preventive care for older Americans with arthritis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Emergence of Legionella pneumophila Pneumonia in Patients Receiving Tumor Necrosis Factor- Antagonists

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk of Herpes Zoster in Patients Receiving Anti-TNF-α in the Prospective French RATIO Registry

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU104

21 January 2018

Identifiers

10.1093/CID/CIU104

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38192553&oldid=1746459180"